Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Biogen Enters $2 Billion Deal to Co-Develop Parkinson's Candidate in US and China

publication date: Aug 6, 2020

Biogen announced a $2 billion blockbuster deal to partner Denali Therapeutics' potential Parkinson's Disease therapy. In exchange for its $1 billion in upfront payments and $1 billion in milestones, Biogen will have rights to partner commercialization of Denali's small molecule LRRK2 inhibitors in the US and China, plus exclusive rights in the rest of the world. The agreement underscores that Denali, a South San Francisco company, considers China's market a significant factor in global marketing plans of its Parkinson's candidate. More details....

Stock Symbols: (NSDQ: BIIB) (NSDQ: DNLI)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020